


































Cisplatin is the most applicable drug for treating various 
human cancers, however, its efficiency is limited due to 
development of drug resistance by tumor cells [1-3]. 
Cisplatin-induced programmed cell death is associated 
with expression of specific ‘‘cell death” genes and 
down regulation of ‘‘survival” genes [1-3]. Failure of 
cancer cells to maintain expression of the former genes 
may be an important factor in cisplatin resistance [1-3].  
Previous reports from our research team emphasized the 
intriguing link between p63 regulatory roles in gene 
transcription and protein stability, and resistance of 
tumor cells to cisplatin chemotherapy [3-5].  P53 
homolog p63 is a novel transcription factor implicated 
in regulation of genes involved in DNA damage 
response and chemotherapeutic stress in tumor cells [3-
6]. Due to the two independent promoters, p63 gene 
encodes two types of protein isotypes, with the long 
transactivation  (TA)-domain  and  with  the  short  TA- 
 
 

































domain [3, 6]. The latter is designated as ΔNp63α. Due 
to several alternative-splicing events p63 produces three 
isotypes with the various length of the carboxyl 
terminus (α, β and γ). ΔNp63α is the longest and is the 
most predominant isotype expressed in squamous cell 
carcinoma (SCC) cells [3-5].  
 
ΔNp63α is phosphorylated by the Ataxia-telangiectasia 
mutated (ATM)-dependent mechanism following 
cisplatin treatment, functioning as a pro-survival factor 
in SCC cells [4, 5].  From the other hand, the ΔNp63α 
ability to activate ATM transcription thereby supports a 
feedback-regulatory mechanism [7]. However, whether 
this transcription factor needs to undergo phospho-
rylation in order to activate ATM transcription remains 
unclear.  Moreover, ATM was shown to translocate to 
cytoplasm where it phosphorylates LKB1 kinase [8, 9] 
subsequently leading to an autophagic process through 
an AMPK/mTOR signaling pathway [10-12]. Finally, 
Phospho-ΔNp63 α /Rpn13-dependent regulation of LKB1 
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www.impactaging.com                    959                                  AGING,   December 2010, Vol.2 No.12cisplatin was shown to induce the phospho (p)-ΔNp63α 
–dependent regulation of the regulatory particle non-
ATPase subunit (Rpn)-13 gene transcription thereby 
contributing to cell death pathway of tumor cells [13].  
Here, we report that upon cisplatin exposure, SCC cells 
displayprotein complex formations between Rpn13, 
ΔNp63α   or LKB1 leading to a proteasome-dependent 
degradation of p-ΔNp63α or LKB1 by binding to 
Rpn13 in turn leading to autophagic-related chemo-












































P- ΔNp63α regulates the ATM transcription 
 
ΔNp63α was previously found to activate the ATM 
transcription in human keratinocytes [7]. This 
transcription factor was shown to induce the ATM 
transcription through the CCAAT element found in the 
human ATM promoter (Fig. 1). As shown in Figure 1, 
the ATM promoter contains a few p63 responsive 
elements (RE) along with E2F and NF-Y cognate 
sequences, where latter one specifically binds to the 
CCAAT element playing a critical role for p-ΔNp63α 
dependent regulation of transcription [5]. Although, 
previous report supports the ability of ΔNp63α to 
induce ATM transcription [7], it is unclear whether the 
ΔNp63α phosphorylation is needed for ATM 
transcriptional regulation.  To access the role for p-
ΔNp63α in the regulation of ATM expression under 
DNA damage, we employed the cellular model, 
isogenic SCC clones, which contain the genomic copy 
of wild type ΔNp6α or  ΔNp63α-S385G. The latter 
protein displays an altered ability to be phosphorylated 
by ATM kinase upon cellular response to cisplatin 
treatment [4, 5].  These clones were used as tools to 
examine the role for phosphorylation of ΔNp63α in 
transcriptional regulation of gene expression and in the 
cellular response to chemotherapeutic treatment 
allowing us to define novel gene targets involved in 
cisplatin-mediated resistance [4, 5].  
 
Using ChIP analysis with antibodies to ΔNp63 and p-
ΔNp63α, we found that cisplatin exposure led to an 
increase of the p-ΔNp63α binding to the ATM promoter 
in wild type ΔNp63α cells, while there is no such 
binding found in ΔNp63α-S385G cells (Fig. 2A). 
Furthermore, p-ΔNp63α binding was associated with 
the specific region of the ATM promoter containing 
NF-Y/ CCAAT element (Fig. 2A). There is no ΔNp63α 
binding was found in the non-specific region of the 
ATM promoter (Fig. 2A).  The quantitative analysis of 
p-ΔNp63α binding by qPCR showed that the cisplatin 
treatment dramatically induced p-ΔNp63α binding to 
the ATM promoter (by ~14.5+1.3 fold) in wild type 
ΔNp63α cells only (Suppl. Fig. S1). 
 
We further tested whether the ΔNp63α phosphorylation 
affects the ability of ΔNp63α to induce the ATM 
promoter-driven luciferase reporter.  Wild type ΔNp63α 
cells and ΔNp63α–S385G cells were transfected with 
the promoter-less pGL3-Luc and pGL3-ATM (1259)-
Luc plasmids followed by the exposure of cells to a con-
trol medium or 10μg/ml  cisplatin  for  24h.  We showed 
Figure  1.  Schematic  representation  of  ATM  (2000  bp)
promoter.  Putative cognate sequences for transription factors
are  bolded,  bordered  and  shadowed.  Several  p63  responsive
elements (RE) were found in the ATM promoter sequence.  
   


















































that the cisplatin treatment significantly increased the 
ATM promoter-driven luciferase activity in wild type 
ΔNp63α cells (by ~4.01+0.34 fold), while no such 
effect (by ~1.06+0.12) was observed in ΔNp63α-S385G 
cells upon cisplatin exposure (Fig. 2B). In addition, 100 
ng of the ΔNp63α-FL expression construct and 
ΔNp63α-S385G-FL construct was introduced into 
ΔNp63α-S385G cells and wild type ΔNp63α cells, 
respectively (Fig. 2B). We observed that ΔNp63α-
S385G-FL markedly attenuated the cisplatin-mediated 
activation of the luciferase activity (by ~1.28+0.12 fold) 
in wild type ΔNp63α cells, while ΔNp63α-FL increased 
this activity (by ~2.39+0.21) in ΔNp63α-S385G cells 
(Fig. 2B).   
 
P-ΔNp63α induces ATM-mediated LKB1-mTOR 
pathway 
 
Recent seminal report by Dr. Cheryl Walker’ group 
clearly demonstrated the stress-dependent export of 
ATM from nucleus to cytoplasm subsequently leading 
to the LKB1 phosphorylation followed by tuberin 
(TSC2) activation and down-regulation of mTOR [8, 9].  
Since  ΔNp63α induces ATM expression [7], we 
suggested the potential role for p-ΔNp63α in ATM 
regulation, ATM translocation to cytoplasm and ATM-
dependent triggering of the LKB1-TSC2-mTOR 
pathway.  We treated wild type ΔNp63α cells and 
ΔNp63α-S385G cells with a control medium and 
10μg/ml cisplatin for 24h. We then found that the 
cisplatin exposure induced the ΔNp63α phosphory- 
lation leading to reduction of ΔNp63α protein levels 
(Fig. 3A).  At the same, the levels of cytoplasmic ATM 
and activated TSC2 were significantly increased, while 
mTOR protein levels were decreased in wild type wild 
type  ΔNp63α cells upon cisplatin exposure (Fig. 3A, 
left panel).  No such changes were observed in 
ΔNp63α-S385G cells (Fig. 3A, right panel). However, 
we showed that the LKB1 levels were decreased in 
ΔNp63α-S385G cells after cisplatin treatment 
suggesting the possibility for LKB1 to be degraded 
(Fig. 3A, right panel). To further examine this 
hypothesis, we exposed cells to lactacystin, the 26S 
proteasome inhibitor [13].  We thus found that the 
lactacystin treatment (25 mM for 12h) rescued ΔNp63α 
degradation in wild type ΔNp63α cells, and LKB1 
degradation in ΔNp63α-S385G cells (Fig. 3B) 
suggesting the critical involvement of the 26S 
proteasome machinery.  
 
Rpn13 binding promotes a proteasome-dependent 
degradation of either p-ΔNp63α or LKB1 
 
A regulatory particle non-ATPase subunit (Rpn)-13 was 
shown to function as a 19S proteasome cap-associated 
protein, acting as an ubiquitin receptor recruiting the 
deubiquitinating enzyme UCH37 to the 26S proteasome 
[13-18]. We previously found that the cisplatin 




ΔNp63α‐S385G cells  (right  panels)  were  exposed  to  a  control
medium  and  10μg/ml  cisplatin  for  24h.  (A)  ChIP  assay  of  a
specific  region  of  the  ATM  promoter  with  anti‐p‐ΔNp63a
antibody  and  anti‐DNp63  antibody.  As  negative  controls,  we
used  ChIP  of  the  ATM  promoter  specific  region  with  rabbit
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Rpn13, UCH37 and NOS2 proteins leading to an 
essential degradation of the latter through a proteasome-







































In this study, we examined whether the Rpn13-
dependent mechanism is implicated in down-regulation 
of the ΔNp63α protein or LKB1 protein in SCC cells 
upon cisplatin exposure. First, we showed that the 
cisplatin treatment reduced the ΔNp63α protein level, 
while induced the ΔNp63α phosphorylation level in 
wild type ΔNp63α cells (Fig. 4A, left panel). At the 
same time, cisplatin up-regulated Rpn13 protein level in 
wild type ΔNp63α cells (Fig. 4A, left panel).  However, 
ΔNp63α and Rpn13 levels were not changed in 
ΔNp63α-S385G cells after cisplatin exposure, while no 
p-ΔNp63α was detected (Fig. 4A, right panel). We 
further showed that the cisplatin exposure induced a 
complex formation between Rpn13, UCH13 and p-
ΔNp63α proteins in wild type ΔNp63α cells  (Fig. 4B, 
left panel), while no such complexes were observed in 
ΔNp63α-S385G cells (Fig. 4B, right panel).  We next 
found that the cisplatin treatment led to a physical 
association between Rpn13, UCH37 and LKB1 proteins 
in ΔNp63α–S385G cells (Fig. 4C, right panel), while no 
similar protein complexes were detected in wild type 







































P-ΔNp63α enhances the autophagic process in SCC 
through a LKB1–dependent pathway 
 
Accumulating evidence supports the notion that stress 
induces autophagic-related characteristics through the 
LKB1-AMPK-TSC-mTOR pathway  [10-12].  We  thus  
 
Figure  3.  Cisplatin  induces  the  p‐ΔNp63α  and  LKB1
protein  levels  in  SCC  cells.  Wild  type  ΔNp63α  cells  and
ΔNp63α‐S385G  cells  were  exposed  to  control  media  and
10μg/ml  cisplatin  for  24h.  Protein  levels  were  tested  with
indicated  antibodies.  Cytoplasmic  (cyto)  protein  levels  were




and between Rpn13  and  LKB1  in ΔNp63α‐S385G  cells.
Wild type ΔNp63α cells and ΔNp63α‐S385G cells were exposed
to  control  media  and  10μg/ml  cisplatin  for  24h.
Immunoprecipitation  (IP)  was  performed  with  indicated
antibodies  and  the  protein  levels  were  tested  with  indicated
antibodies.  (A)  Immunoblotting.  (B)  and  (C)  Immino‐
precipitation.  
   
www.impactaging.com                    962                                  AGING,   December 2010, Vol.2 No.12examined whether cisplatin treatment promotes the 
autophagy, and whether LKB1- or Rpn13- dependent 
mechanisms play any role in it. Microtubule-associated 
protein light chain 3 (LC3B), a mammalian homolog of 
yeast Atg8, has been used as a specific marker to 
monitor autophagy [19]. Upon induction of autophagy, 
the cytosolic form LC3B (LC3B-I) is conjugated to 
phosphatidylethanolamine  (conversion into LC3B-II) 














































The S385G mutation shown to impair the ability for 
ΔNp63α to be phosphorylated by ATM in SCC cells 
upon cisplatin treatment is a superficial tool providing a 
suitable model system to investigate a potential 
relationship between ΔNp63α and ATM-dependent 
phosphorylation. Thus, we used this model to assess a 
role for ATM-dependent phosphorylation of the 
ΔNp63α in cisplatin chemoresistance of SCC cells. 
Wild type ΔNp63α cells and ΔNp63α–S385G cells 
were transiently transfected with scrambled siRNA, 
siRNA against Rpn13 or LKB1 for 24h and then 
exposed to control media or 10μg/ml cisplatin for 24h 
in the presence of 10μg/ml of lyzosomal protease 
inhibitors, E64d and pepstatin A, as recommended 
elsewhere [19].  By immunoblotting with an antibody 
against an autophagosome marker, LC3B-I (16 kDa) 
and its conversion variant LC3B-II (14 kDa), we 
observed the cisplatin-induced autophagy-related 
changes of LC3B expression in SCC cells (Fig. 5).  We 
found that wild type ΔNp63α cells (which support the 
ΔNp63α phosphorylation in response to cisplatin) 
displayed a marked expression of LC3B-II, while 
siRNA against LKB1 dramatically reduced this effect. 
Interestingly, siRNA against Rpn13 had a minimal 
effect on the cisplatin-induced LC3B-II activation (Fig. 
5A, left panel).  From the other hand, cisplatin treatment 
failed to induce autophagic changes in LC3B expression 
in  ΔNp63α-S385G cells (Fig. 5A, right panel). 
Intriguingly, siRNA against Rpn13 markedly increased 
the level of the LC3B-II autophagic marker in 
ΔNp63α−S385G cells (Fig. 5A, right panel) suggesting 
the Rnp13-dependent regulation of LKB1 protein levels 
in these cells.  
  
We also employed a set of SCC cells displaying 
sensitivity or resistance to cisplatin (SCC-25 and SCC-
25CP, respectively) as reported elsewhere [20].  We 
first examined whether SCC-25 and SCC-25CP cells 
expressed  ΔNp63α or p-ΔNp63α in response to 
cisplatin treatment. We found that after cisplatin 
exposure, resistant SCC-25CP cells, indeed, express far 
less of the p-ΔNp63α protein than their sensitive 
counterpart, SCC-25 (Suppl. Fig. S2). We further found 
that, in constrast to SCC-25 cells, cisplatin reduced the 
LKB1 protein levels in SCC-25CP cells (Suppl. Fig. S2) 
suggesting that the greater ratio between non-
phosphorylated  ΔNp63α and p-ΔNp63α might be an 
important factor contributing to LKB1 reduction and is 
likely to play a role in cisplatin resistance displayed by 
SCC-25CP cells.  
 
We further found that cisplatin induced the LC3B-II 
expression in sensitive SCC-25 cells, while siRNA 
against LKB1 significantly inhibited this expression, 
and siRNA against Rpn13 had only a minimal effect on 
Figure 5. Cisplatin induces the autophagic process through
a LKB1 up‐regulation. (A) Wild type ΔNp63α cells and ΔNp63α ‐
S385G  cells  and  (B)  Sensitive  (SCC‐25)  and  resistant  (SCC‐25CP)





were  analyzed  by  immunoblotting  with  indicated  antibodies.  β‐
actin expression was used as a loading control.  (C). Quantitative




LC3B‐II/LC3B‐I  ratios  were  plotted  as  bars  using  the  Microsoft
Excel  software  with  standard  deviations  (+SD,  p>0.05)  resulting
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case of resistant SCC-25CP cells, one could see no 
cisplatin-induced LC3B-II up-regulation, however 
siRNA against Rpn13 promoted a significant increase 
of this autophagic marker (Fig. 5B, right panel).  The 
quantitative analysis of the LC3B-I/LC3B-II ratio (Fig. 
5C) led us to the same conclusion. Using immuno-
fluorescence analysis, we further examined the 
expression of LC3B-II isotype in SCC upon cisplatin 
exposure and observed the clustering (“punctuated 
appearance”) of the membrane-associated protein, MAP 
LC3α/β (LC3B), as previously described elsewhere [19, 
21]. We also observed that cisplatin-resistant cells 
showed much lesser autophagic-related levels of LC3B-
II expression than cisplatin-sensitive cells (Fig. 6) 
suggesting the critical role for autophagy in tumor 




































An optimal cellular response to DNA damage/stress 
(ionizing radiation, oxidative stress, chemotherapeutic 
drugs, UV radiation, nutrient deprivation, and hypoxia) 
requires repair of damage and coordination of critical 
cellular processes such as transcription, translation, 
metabolism, and control of cell survival through an 
apoptosis or autophagy [22-26].  
 
Emerging evidence supports the notion that the 
cisplatin-induced autophagy plays a central role in 
tumor cell resistance to platinum-based therapy [27-29].  
A dose- and time-dependent induction of autophagy 
observed in tumor cells following cisplatin treatment is 
evidenced by up-regulation Beclin-1 and cisplatin-
triggered activation of AMPK pathway leading to a 
subsequent suppression of mTOR activity [28]. 
Autophagy is also shown to delay apoptosis in renal 
tubular epithelial cells exposed to cisplatin cytotoxicity 
[30, 31]. The switch from autophagy to apoptosis 
suggests that autophagy induction mediates a pre-
apoptotic lag phase observed in renal tubular cells 
exposed to cisplatin supporting the idea that autophagy 
mounts an adaptive cell response that delays apoptosis 
and might contribute to a cisplatin resistance in other 
cellular systems including cancer [30, 31].  
 
A few oncogenes (e.g. phosphatidylinositol 3-kinase, 
activated AKT1) inhibit autophagy, while numerous 
tumor suppressors (e.g. BH3-only proteins, death-
associated protein kinase-1, PTEN, tuberous sclerosic 
complex 1 and 2, TSC1 and TSC2 and LKB1/STK11) 
induce autophagy [32]. As known guardians of genome 
integrity, p53 and p73, were shown to be involved in 
autophagic processes [24, 25, 33-37]. However, to date 
no evidences were reported that p63 plays a role in 
autophagic pathway. 
 
ATM is a biosensor that coordinates cellular response to 
various damaging signals to preserve genomic integrity 
[8, 9, 22, 23]. ATM has been recently implicated in 
cellular response to elevated reactive oxygen species 
(ROS) and therefore involved in redox homeostasis [8, 
9, 22]. The key reports of the Cheryl Walker’ research 
team showed that the ATM import to cytoplasm 
activates the specific phosphorylation of LKB1 at the 
Threonine-366 position leading to subsequent TSC2 
activation via the LKB1/AMPK metabolic pathway, and 
reduction of mTOR level, in turn promoting autophagy 
[8, 9]. 
 
Our previous observations showed that the cisplatin 
exposure induced the ATM-dependent phosphorylation 
of  ΔNp63α resulting in the p(S385)-ΔNp63α 
modification and subsequently leading to a proteasome-







LC3α/β  (1:100),  and  then  photographed  under  fluorescent
microscope.  
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transcriptional regulation of numerous gene targets 
involved in tumor cell response to cisplatin, some of 
them with pro-apoptotic functions and some – with cell 
survival functions [5].  The complex response of the p-
ΔNp63α dependent gene targets to cisplatin prompted 
us to continue the quest for the signaling pathways 
leading to cisplatin sensitivity or cisplatin resistance 
displayed by tumor cells [3-5].  Recent observations by 
the research groups of Ted Hupp and Borivoj Vojtesek 
defined ΔNp63α as a novel regulator of p53 activation 
through the ATM kinase transcription [7]. They further 
reported that the ΔNp63α protein interacts with the 
ATM promoter-derived CCAAT sequence [38], 
previously shown to be critical for the p-ΔNp63α 
transcription function in SCC upon cisplatin exposure 
[5]. Intriguingly, these investigators showed that 
DNp63α activates the ATM gene transcription, whereas 
TAp63α does not, highlighting an essential role for the 
TA2 domain in mediating ΔNp63α function [7]. 
 
In this study, we found that p-ΔNp63α binds the ATM 
promoter, induces the ATM promoter activity and 
activates the ATM cytoplasmic accumulation. We 
further found that the p-ΔNp63α protein interacts with 
the Rpn13 protein leading to a proteasome-dependent 
degradation of p-ΔNp63α. Next, we observed that ATM 
triggers the LKB1-AMPK-tuberin pathway leading to a 
down-regulation of mTOR subsequently enhancing the 
cisplatin-dependent autophagy in wild type ΔNp63α 
cells upon cisplatin exposure.  Using the SCC cells with 
an altered ability to support the ATM-dependent 
ΔNp63α phosphorylation, non-phosphorylated ΔNp63α 
failed forming protein complexes with Rpn13 and 
allowing the latter to bind and target LKB1 into a 
proteasome-dependent degradation pathway thereby 
modulating a cisplatin-induced autophagy.  SCC cells 
with the innate resistant/impaired response to a 
cisplatin-induced cell death displayed a greater ratio of 
non-phosphorylated ΔNp63α/p-ΔNp63α than cells that 
are sensitive to cisplatin-induced cell death. Based on 
our findings so far, we suggest that the choice made by 
Rpn13 between p-ΔNp63α or LKB1 to be targeted for 
degradation is critical for cell death decision made by 
cancer cells in response to chemotherapy.  The 
discovery that the ΔNp63 promoter is subject to both 
p53-mediated activation and repression by ΔNp63α 
[39], and that ATM-dependent phosphorylation 
mediates  ΔNp63α degradation [4, 5] suggests that 
activity of the damage-response ΔNp63α-ATM-p53 
pathway is finely modulated by complex feedback 
mechanisms [7]. Further dissection of this pathway 
should provide molecular targets for combating cancer 
and ageing [7, 9, 40-44].   
METHODS 
 
Cells and reagents. We have used the head and neck 
squamous carcinoma (SCC) stable cell lines expressing 
wild type ΔNp63α or ΔNp63α-S385G (with an altered 
ability to be phosphorylated by ATM kinase) as 
previously described [4, 5]. We also used cisplatin-
sensitive (SCC-25) and resistant (SCC-25CP) squamous 
carcinoma cell lines obtained from Dr. J.S. Lazo 
(Department of Pharmacology, University of Pittsburgh 
School of Medicine) as a result of the Material Transfer 
Agreement [20].  Cells were maintained in RPMI 
medium 1640, 10% fetal bovine serum. Cells were 
incubated with 10 μg/ml cisplatin, 25 μM of lactacystin 
β-lactone (Calbiochem) for indicated periods of time, as 
described elsewhere [13].  Cells were lysed in 50 mM 
Tris, pH 7.5, 100 mM NaCl, 2mM EDTA, 0.5% Triton 
X-100, 0.5% Brij-50, 1 mM PMSF, 0.5 mM NaF, 0.1 
mM Na3VO4, 2X protease inhibitor cocktail, sonicated 
for 10 sec time intervals, and clarified for 30min at 
15,000xg. Supernatants (total lysates) were used for 
immunoprecipitation and immunoblotting [4, 5, 13]. 
Control (scrambled) siRNA and Rpn13 siRNA (sc-
72453) were obtained from Santa Cruz Biotechnology, 
while siRNA against LKB1 was purchased from 
Dharmacon [45]. SiRNAs  (200 pmol/six-well plate) 
were transiently transfected into cells using FuGENE 6 
(4 μL, Roche) for 24h and then after the 24h treatment 
with control media or 10μg/ml cisplatin.  
 
Isolation of cytoplasmic fraction.  1–2 × 10
6 cells were 
resuspended in a hypotonic lysis buffer (10 mM HEPES 
pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA) 
with protease inhibitors (Sigma), Triton X-100 (0.6% 
final concentration) was then added and the nuclei were 
pelleted at 2,500-3,000xg for 10 min at 4°C. 
Supernatants served as cytoplasmic fractions [13].  
 
Antibodies.  We used a rabbit polyclonal antibody 
against  ΔNp63α (Ab-1, EMD Chemicals), a mouse 
monoclonal antibody against β-actin (Sigma), and rabbit 
polyclonal antibodies against UCH3 (ab38528), mTOR 
(ab2833) and Rpn13 (ab91567), and a mouse 
monoclonal antibody against ATM (2C11A1, ab78) 
were purchased from Abcam. We also obtained a mouse 
monoclonal antibody against Rpn13 (M01, clone 3C6, 
Abnova). A mouse monoclonal anti-LKB1 antibody 
(clone 27D10, ab3050) was obtained from Cell 
Signaling Technology. A custom rabbit polyclonal 
antibody against p ΔNp63α (ATM motif, residues 379-
392) was previously described [4].  A polyclonal rabbit 
anti-phospho-tuberin antibody (TSC2-S1387, AP3338a; 
which represents the AMPK-dependent phosphoryla-
tion) was obtained from Abgent.  
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6 
cell equivalents of chromatin (2–2.5 kb in size) were 
immunoprecipitated (IP) with 10 μg of anti-p ΔNp63α 
antibody as described elsewhere [5, 13].  After reversal 
of formaldehyde crosslinking, RNAase A and 
proteinase K treatments, IP-enriched DNAs were used 
for PCR amplification.  PCR consisted of 40 cycles of 
94°C for 30 s, 60°C for 30 s, and 72°C for 30 s using 
Taq DNA polymerase (Invitrogen). The following PCR 
primers were used for amplification of the ATM 
promoter: for the specific region, sense, (-920) 5’- 
TTCAGGGGTCCTAATTAAGT -3’(901), and 
antisense, (-570) 5’- TGATCAAAACCACAGCAGG-
3’ (-551) yielding the 350 bp PCR product, and for the 
non-specific region, sense, (-2000) 5’- 
TAGGGGTGATTCTGCCCTCC-3’ (-1880) and 
antisense, (-1821) 5’- AATTATGAGGCCCAAAATG-
3’ (-1802) yielding the 199 bp PCR product.  Binding of 
the endogenous p-ΔNp63α protein to the ATM 
promoter was also assessed by qPCR using the above-
mentioned primers for the specific region of the ATM 
promoter as previously described [13]. ChIP-PCR 
values (relative units, RU) were normalized by the 
GAPDH values and those obtained from the control 
samples (cells treated with control medium) were 
designated as 1. Experiments were performed in 
triplicate. 
 
Luciferase reporter assay. We used the pGL3-ATM 
(S118526, SwitchGear Genomics) promoter-luciferase 
reporter plasmid (encompassing  -1259 bp to +1 bp of 
the ATM promoter). A total of 5x10
4 cells/well in a 24-
well plate were transfected with 100 ng of the pGL3 
luciferase reporter constructs plus 1 ng of the Renilla 
luciferase plasmid pRL-SV40 (Promega) using 
FuGENE 6 (Roche) as previously described [3, 13]. At 
24h, cells were also treated with 10 μg/ml cisplatin or 
control medium and then after an additional 24h, 
luciferase assays were performed using the Dual 
luciferase reporter assay kit (Promega). For each 
experiment, the wells were transfected in triplicate and 
each well was assayed in triplicate by measuring the 
Firefly luciferase activity in a luminometer. Renilla 
luciferase activity was measured in the same tube 
[3,13]. The values for Firefly luciferase activity were 
normalized against the Renilla luciferase activity values 
for each transfected well.  Resulting data were 
presented as relative luciferase units (RLU). 
 
Autophagy assay. Cells were transiently transfected 
with scrambled siRNA, siRNA against Rpn13 or LKB1.  
Cells were exposed to control medium or 10 μg/ml 
cisplatin for 24h in the presence of lyzosomal protease 
inhibitors (10μg/ml of both E64d and pepstatin A 
purchased from Sigma) as previously described [19]. 
Protein levels of LC3B-I and LC3B-II were tested with 
a rabbit polyclonal antibody against MAP LC3α/β 
(LC3B, L7453, Sigma Aldrich Co). Immunoblots were 
scanned using PhosphorImager (Molecular Dynamics) 
and quantified by ImageQuant software version 3.3 
(Molecular Dynamics). Values of LC3B-II were 
expressed as a portion of LC3B-I values defined as 1. 
The LC3B-II/LC3B-I ratios were plotted as bars using 
the Microsoft Excel software with standard deviations 
(+SD) resulting from three independent experiments 
and three individual measurements of each experiment. 
 
Immunofluorescence microscopy.  Cells were washed 
with ice-cold phosphate-buffered saline and after 
fixation with 4% paraformaldehyde for 10 min at room 
temperature, they were permeabilized with 50μg/ml 
digitonin for 5 min. Cells were then quenched in 0.1% 
sodium borohydride for 5 min, and blocked with 10% 
goat serum, 1% bovine serum albumin (BSA, 
Amersham Biosciences) at room temperature for 60 
min. Cells were incubated overnight with the primary 
antibody against MAPLC3α/β diluted in 1% BSA at 4 
°C. After washing, the cells were incubated with the 
Cy3-conjugated anti-rabbit antibody (1:500, Jackson 
ImmunoResearch Laboratories Inc) diluted in 1% BSA 
for 1h. Finally, images were obtained using a Leica 
TCS-NT laser scanning microscope system and 
processed with Adobe Photoshop software [29-31]. 
 
Statistical analysis.  The data represent mean ± SD from 
three independent experiments and the statistical 
analysis was performed by Student's t test at a 
significance level of p<0.05 to <0.001.  
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Supplemental Figure S1. Quantitative PCR analysis of the ChIP binding.
Wild type ΔNp63α cells and ΔNp63α‐S385G cells were treated with the control













medium  (CIS, ‐ )  or  10μg/ml  cisplatin  (CIS,  +)  for  24h.
Immunoblotting of total lysates was performed with indicated
antibodies and loading level was monitored by the β‐actin level. 
 